Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Odronextamab in Richter's Transformation
NCT06735664Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib and odronextamab in Richter's transformation (RT), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicity and Adverse Events. Started Aug 2025; status: recruiting.
02
Drugs
zanubrutinibodronextamab
03
Conditions
Richter's transformation (RT)
Beyond the preview
Go deeper on NCT06735664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735664.